The Calcium Sensitizer Levosimendan Improves Human Diaphragm Function

Jonne Doorduin1, Christer A. Sinderby2,3, Jennifer Beck1,4, Dick F. Stegeman5,6, Hieronymus W. H. van Hees7, Johannes G. van der Hoeven1, and Leo M. A. Heunks1

1Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre, The Netherlands; 2Department of Medicine, Division of Critical Care Medicine, University of Toronto; 3Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto; 4Department of Pediatrics, St. Michael’s Hospital, University of Toronto, Toronto, Canada; 5Department of Neurology, Radboud University Nijmegen Medical Centre, The Netherlands; 6Faculty of Human Movement Sciences, Research Institute MOVE, VU University, Amsterdam, The Netherlands; and 7Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Rationale: Acquired diaphragm muscle weakness is a key feature in several chronic conditions, including chronic obstructive pulmonary disease, congestive heart failure, and difficult weaning from mechanical ventilation. No drugs are available to improve respiratory muscle function in these patients. Recently, we have shown that the calcium sensitizer levosimendan enhances the force-generating capacity of isolated diaphragm fibers.

Objectives: To investigate the effects of the calcium sensitizer levosimendan on in vivo human diaphragm function.

Methods: In a double-blind, randomized, crossover design, 30 healthy subjects performed two identical inspiratory loading tasks. After the first loading task, subjects received levosimendan (40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion) or placebo. Transdiaphragmatic pressure, diaphragm electrical activity, and their relationship (neuromechanical efficiency) were measured during loading.

Conclusions: The calcium sensitizer levosimendan improves neuromechanical efficiency and contractile function of the human diaphragm. Our findings suggest a new therapeutic approach to improve respiratory muscle function in patients with respiratory failure.

Keywords: diaphragm; muscle weakness; calcium sensitization; levosimendan

Impaired force generation of the respiratory muscles has been recognized in a variety of diseases, including chronic obstructive pulmonary disease (COPD) and congestive heart failure, and in critically ill patients (1–7). The pathophysiological substrate of diaphragm dysfunction in these disorders is multifactorial and includes muscle fiber atrophy and contractile protein dysfunction (3, 8–11). We found that diaphragm muscle fibers of patients with COPD display reduced sensitivity of the contractile proteins to calcium (9, 12). In other words, more calcium is needed to develop the same amount of force as in the non-COPD diaphragm, resulting in impaired contractile efficiency of the diaphragm muscle. Subsequent studies have shown that calcium sensitivity is also reduced in the diaphragm of animal models of congestive heart failure and prolonged mechanical ventilation (2, 13). Despite a better understanding of respiratory muscle dysfunction in chronic diseases, no drug is available to improve respiratory muscle function in humans.

Levosimendan is a clinically used calcium sensitizer that has been approved to enhance cardiac contractility in patients with acute heart failure. Clinical studies have shown that levosimendan improves cardiac function in these patients (14). Levosimendan enhances the binding of calcium to troponin C, thereby improving the responsiveness of myofilaments to calcium. Accordingly, a greater amount of force is generated for the same level of cytosolic calcium, resulting in enhanced contractile efficiency. Levosimendan has vasodilatory properties mediated by the opening of the ATP-sensitive potassium (KATP) channels (15).

Recently, we have shown that levosimendan enhances calcium sensitivity of permeabilized muscle fibers obtained from the human diaphragm, including patients with COPD (12). However, the effects of calcium sensitizing on the human diaphragm in vivo have not been studied. Based on our in vitro data (12), we

(Received in original form July 14, 2011; accepted in final form September 13, 2011)

Supported by institutional resources.

Author contributions: Literature search, J.D., L.H.; study design, J.D., C.S., J.B., D.S., L.H.; data collection, J.D., L.H.; data analysis, J.D., L.H.; data interpretation, J.D., C.S., J.B., D.S., H.H., J.H.; writing, J.D., C.S., J.B., D.S., H.H., J.H., L.H. Correspondence and requests for reprints should be addressed to Leo Heunks, M.D., Ph.D., Radboud University Nijmegen Medical Centre, Department of Critical Care Medicine, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands. E-mail: L.Heunks@ic.umcn.nl

This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org

Am J Respir Crit Care Med Vol 185, Iss. 1, pp 90–95, Jan 1, 2012
Copyright © 2012 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201107-1268OC on September 29, 2011
Internet address: www.atsjournals.org

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Respiratory muscle weakness frequently occurs in chronic diseases and contributes to morbidity and mortality. There is no specific pharmacological treatment available to improve respiratory muscle function in patients with impending respiratory muscle failure. Previous studies have demonstrated that calcium sensitizers improve in vitro function of the respiratory muscles.

What This Study Adds to the Field

We report that the calcium sensitizer levosimendan improves neuromechanical efficiency of the human diaphragm. In addition, levosimendan restored the loss of diaphragm contractility after an intervention of loaded breathing. These findings suggest that levosimendan treatment may be an effective strategy to improve muscle function in patients with respiratory muscle weakness.
hypothesize that levosimendan improves contractile function of
the human diaphragm in vivo through calcium sensitizing
and that levosimendan would decrease muscle fiber conduction velocity
of the diaphragm through its effects on K_{ATP} channels in
diaphragm fibers. We tested this hypothesis in a double-blind,
placebo-controlled, crossover design in healthy subjects performing
inspiratory loading tasks. Some of the results of this study
have been previously reported in the form of an abstract (16).

METHODS
We enrolled 30 healthy volunteers in this trial. The protocol was
approved by the ethical committee of the Radboud University Nijmegen
Medical Centre and registered at ClinicalTrials.gov (NCT01101620).
All subjects gave their informed consent.

Esophageal Catheter
Diaphragm electromyographic activity (EMGdi), esophageal pressure
(Pes), and gastric pressure (Pga) were obtained with a multielectrode
esophageal catheter with two balloons (details are provided in the on-
line supplement). Transdiaphragmatic pressure (Pdi) was calculated as
Pga − Pes.

Magnetic Stimulation and Maximal Inspiratory Effort
Cervical magnetic stimulation of the phrenic nerves was performed to
measure twitch Pdi (Pdi_tw) and compound muscle action potential of
the diaphragm (CMAPdi). Details about the stimulation protocol are
provided in the online supplement.

Maximal voluntary Pdi (Pdi_max) was measured as mean Pdi in the
first second during a maximal inspiratory effort against a closed valve
at functional residual capacity.

Inspiratory Loading Task
Each subject performed two identical loading tasks, one before and one
after administration of the study medication. Sitting in upright position
with uncast abdomen, subjects breathed through a mouthpiece while
wearing a nose clip. Subjects performed intermittent inspiratory maneuvers
of 10 seconds against a closed valve (near-isometric contractions)
followed by 7 seconds of unloaded breathing. Duty cycle was imposed by
a sound signal, and subjects were asked to target 40% of Pdi_max. Visual
feedback of Pdi was provided. Total loading task duration was 10
minutes. During loading, EMGdi and Pdi were recorded continuously,
as well as in unloaded conditions approximately 5 minutes before and
after loading. Respiratory effort sensation was scored with a Borg scale
(range, 6–20) at 1, 3, 6, and 9 minutes into loading.

Experimental Protocol
The protocol is presented in Figure 1. Pdi_tw and Pdi_max were measured and
followed by the first loading task and 30 minutes of unloaded breathing.
After randomization, subjects received levosimendan bolus (40 µg/kg
bodyweight, intravenously) or an equal volume of placebo in 10 minutes.
Pdi_tw and Pdi_max measurements were repeated and followed by 30 minutes
of continuous levosimendan (0.1 µg/kg bodyweight/min, intravenously) or
placebo infusion. A second loading task was performed while infusion
levosimendan (0.2 µg/kg/min, intravenously) or placebo.

Heart rate, end tidal carbon dioxide (etCO₂), and peripheral oxygen
saturation (SpO₂) were monitored continuously. Blood pressure was
measured noninvasively every 10 minutes and during bolus administra-
tion each minute. In six subjects, cardiac output was determined by
transathoric echocardiography directly before and after bolus
administration.

Data Analysis and Statistics
Measurement variables were analyzed offline in Matlab R2009b
(The Mathworks, Natick, MA) (details are provided in the online sup-
plement). The ratio of mean inspiratory Pdi and EMGdi amplitude
was calculated as a measure of the neuromechanical efficiency of the
diaphragm. Changes in muscle fiber conduction velocity were evaluated
using the power spectrum center frequency (CFdi) of the EMGdi (details
are provided in the online supplement). Comparisons were made with
the appropriate t test. Changes over time during loaded breathing were
analyzed using repeated measures ANOVA. Values are means ± SEM,
and P < 0.05 was considered significant. Statistical analyses were per-
formed with SPSS 16.0 (SPSS, Chicago, IL).

RESULTS
Baseline characteristics of the subjects (male/female, 23/7; age,
22 ± 0.4 yr; bodyweight, 74 ± 1 kg; and body mass index, 23 ±
0.4 kg/m²) were not different between the placebo and levosi-
menad groups. All subjects (n = 30) received study medication
as dictated by the protocol. One subject was excluded due to
technical problems with the esophageal catheter. Two subjects
were not able to maintain targeted Pdi (< 30% of Pdi_max) dur-
ing the first loading task and were excluded from data analysis.
The remaining subjects (placebo, n = 13; levosimendan, n = 14)
were able to keep their targeted Pdi during both loading tasks
(44 ± 1% and 43 ± 2%), indicating compliance to the protocol.
SpO₂ was above 96% in all subjects during the study; no supple-
mental oxygen was given. There were no differences in etCO₂
between the placebo and levosimendan group during loaded
breathing.

Furthermore, there were no serious adverse events during the
experimental protocol. One subject, receiving levosimendan, ex-
perienced a mild degree of nausea after completion of the study.

Diaphragm Contractility
Cervical magnetic stimulation of the phrenic nerves resulted in
reproducible twitch pressures in all subjects. Data from magnetic
stimulation and maximal inspiratory maneuvers, as well as he-
modynamic data, are given in Table 1. There was no significant
difference in Pdi_tw and Pdi_max between the placebo and the
levosimendan groups before study medication.

Figure 2 shows a decreased contractile response of the dia-
aphragm after the first loading task in a subject receiving placebo.

![Figure 1. Schematic description of the protocol. Pdi_max = maximum
transdiaphragmatic pressure; Pdi_tw = twitch transdiaphragmatic pressure.](Image 303x484 to 548x737)
On average, loaded breathing in subjects receiving placebo resulted in significant reductions in $P_{di_{tw}} (-9 \pm 3\%$; $P = 0.01$) and $P_{di_{max}} (-5 \pm 3\%; P < 0.05)$. The group receiving levosimendan after the first period of loaded breathing revealed no significant decrease in $P_{di_{tw}}$ and $P_{di_{max}}$ (Figure 3; Table 1).

### Neuromechanical Efficiency of the Diaphragm

In Figure 4, representative tracings of EMGdi and Pdi are presented for the first loading task (before study medication) and the second loaded task (with study medication) for both groups. Neuromechanical efficiency of the diaphragm ($P_{di}/EMG_{di}$) in the first loading task was not different between the placebo and the levosimendan groups (both $1.3 \pm 0.2$ cm H$_2$O/µV) and remained stable throughout the loading task (Figure 5). Neuromechanical efficiency during unloaded breathing and during the second loading task was improved by 21% ($P < 0.05$, compared with the first loading task) in the levosimendan group, whereas neuromechanical efficiency was not affected in the placebo group (Figure 5). The improved neuromechanical efficiency in subjects receiving levosimendan sustained throughout the entire loading task.

### Center Frequency of Diaphragm Electrical Activity

During both loaded breathing protocols, CFdi decreased over time ($P < 0.001$) (see Figure E1 in the online supplement) in both groups. Administration of levosimendan resulted in a downward shift in baseline CFdi during the second loaded breathing protocol ($P < 0.05$; Figure E1), whereas placebo did not affect CFdi.

### Respiratory Effort Sensation

Respiratory effort sensation increased over time ($P < 0.001$) during loaded breathing until a score of 16 was reached. Neither levosimendan nor placebo affected respiratory effort sensation.

### DISCUSSION

The present study is the first to evaluate the effect of the calcium sensitizer levosimendan on human diaphragm function in vivo. In this double-blind, randomized study, an intervention of loaded breathing resulted in significant loss of diaphragm contractility in the placebo group but not in the levosimendan group, suggesting that levosimendan restored diaphragm contractility. Loaded breathing after drug administration was associated with improved neuromechanical efficiency of the diaphragm in the levosimendan group. Furthermore, levosimendan reduced baseline center frequency of diaphragm electrical activity. Levosimendan was well tolerated with negligible side effects.

### Calcium Sensitivity and Muscle Fiber Conduction Velocity: Effects of Levosimendan

Skeletal muscle force develops as intracellular calcium rises and binds to troponin C, resulting in conformational changes in the troponin complex, allowing interaction between actin and myosin to form force-generating cross-bridges. Reuptake of calcium from the cytoplasm into the sarcoplasmic reticulum is a high energy-consuming process (up to 40% of total energy expenditure). Thus, reduced sensitivity of the troponin complex for calcium requires higher levels of cytoplasmic calcium to generate the same amount of force, requiring higher energy consumption and elevated CO$_2$ production.

Levosimendan belongs to a relatively new class of drugs, the calcium sensitizers and is approved in more than 40 countries worldwide to improve cardiac function in patients with acute heart failure (14). Although the loading dose of levosimendan in this study is higher than recommended for the treatment of...
ever, levosimendan reversed the development of fatigue; Pdi tw increased by 21% after administration of levosimendan (Figure 5). A 21% decrease in CFdi over time indicates the development of reduced muscle fiber conduction velocity [see the online supplement for details]. Reduced muscle fiber conduction velocity is an increased difficulty of muscle fiber action potentials to propagate along the sarcolemma and into T tubuli (22). Therefore, the downward shift in baseline CFdi in subjects receiving levosimendan most likely reflects a baseline decrease in muscle fiber conduction velocity. These data are in line with the established effects of levosimendan on KATP channel activation (15) and with the finding that extracellular [K⁺] accumulation contributes to reduced muscle fiber conduction velocity (23, 24). Because administration of levosimendan improves neuromechanical efficiency of the diaphragm by 21%, it is unlikely that extracellular [K⁺] accumulation results in functional impairment of the diaphragm. Moreover, preserving a hyperpolarized sarcolemma by activating KATP channels might play a myoprotective role under conditions of metabolic stress (25).

Enhancing calcium sensitivity with levosimendan appears to be a rational and effective approach to improve respiratory muscle function, in particular in patients with imminent respiratory failure.

Clinical Implications

Reduced force generation of the respiratory muscles has been demonstrated in numerous disorders, including COPD, congestive heart failure, pulmonary hypertension, and patients on mechanical ventilation (1–7). There are no pharmacological interventions available to improve respiratory muscle function.

Aubier and colleagues have previously shown that dopamine (26) and aminophylline (27) improve contractility of the human diaphragm, although the effects of aminophylline are controversial (28). Neither dopamine nor aminophylline has been used in clinical practice to optimize respiratory muscle function, probably due to the small therapeutic window, the risk of severe side effects (aminophylline, dopamine), and the very short half-life (dopamine). Instead, the active levosimendan metabolite OR-1896 has a half-life of 70 to 80 hours, resulting in clinical effect up to 1 week after 24-hour infusion (29). More importantly, both aminophylline and dopamine improve contractility by elevating intracellular calcium concentration, resulting in an increased ATP utilization. As discussed elsewhere (12), inorganic phosphate accumulation contributes to the development of muscle fatigue and depresses calcium sensitivity (30). In addition, elevated energy expenditure increases CO₂ production, requiring a higher level of ventilation. This limits the clinical utility of these drugs for the improvement of respiratory muscle function in patients with imminent ventilatory failure. Rather, calcium sensitizers improve muscle contractility without elevating energy expenditure (31). In addition, more efficient breathing may hasten liberation from mechanical ventilation (32). This may be important for patients with respiratory failure, such as acute exacerbation of COPD. Of note, our previous in vitro work showed that the effect of levosimendan is more profound in type-1 diaphragm fibers than in type-2 fibers (12). Because a fiber type shift toward type-1 fibers is known to occur in the diaphragm of patients with COPD (8) and congestive heart failure (33), levosimendan treatment can potentially be more effective in these patients than in healthy subjects. Accordingly, the rationale for evaluating the effect of levosimendan on respiratory muscle function in patients with respiratory failure appears highly appropriate.

Experimental Model

The contractile performance of the diaphragm was evaluated using magnetic stimulation and maximal inspiratory efforts.

Figure 3. Percentage change in transdiaphragmatic twitch pressure (Pdi tw) from baseline after loading + bolus administration in the placebo (open circles) group. Data are presented as mean ± SEM (placebo, n = 13; levosimendan, n = 14). *Significantly different from baseline (P = 0.01) and levosimendan group after loading + bolus administration (P = 0.01).
Thus increased neuromechanical efficiency of the diaphragm. The subject receiving levosimendan shows decreased neural activation compared to placebo, there is no change in EMGdi (i.e., neural activation), whereas subjects in the placebo group during the second loaded breathing task. Thus, the neuromechanical efficiency of the phrenic diaphragm was not reduced in the placebo group during the second loaded breathing task. We also found that, despite evidence of twitch force loss, the diaphragm contractility was not reflected in the placebo group during the second loaded breathing task. W e found that diaphragm neuromechanical efficiency at 40% of Pdi max was constant over time and that CFdi decreased over time during loaded breathing, which are in line with previous data from Sinderby and colleagues (36). Magnetic stimulation has a clear benefit over voluntary maneuvers because it is effort independent and highly reproducible (34). Values for Pdi tw and Pdi max reported in our study are similar to those reported by other groups for healthy subjects (20, 35). Due to coincidence, baseline Pdi tw and CMAPdi amplitude were lower (though insignificant) in the levosimendan group (Table 1), suggesting these subjects were more difficult to stimulate. Correcting for CMAPdi amplitude abolished the baseline difference between the groups (data not shown).

To further evaluate the function of the diaphragm, we measured neuromechanical efficiency of the diaphragm (Pdi/EMGdi) during inspiratory loaded breathing. We found that diaphragm neuromechanical efficiency at 40% of Pdi max was constant over time and that CFdi decreased over time during loaded breathing, which are in line with previous data from Sinderby and colleagues (36). We also found that, despite evidence of twitch force loss, the diaphragm neuromechanical efficiency was not reduced in the placebo group during the second loaded breathing task. Thus, the reductions in maximal contractility were not reflected in the placebo group during the second loaded breathing task. Therefore, it is unlikely that an improved cardiac output (and oxygen delivery) would explain the restored diaphragm contractility with levosimendan. Moreover, levosimendan improved efficiency already during unloaded breathing and immediately at the start of the loading task, which is unlikely to be the result of improved oxygen delivery to the diaphragm.

The dosage of levosimendan used in the current study was derived from earlier studies in healthy subjects that demonstrated limited side effects (39). This is in line with our study. Future studies should evaluate the effects of lower doses of levosimendan on respiratory muscle function in humans.

In conclusion, the present study demonstrates that the calcium sensitizer levosimendan improves contractile function and neuromechanical efficiency of the human diaphragm. These findings suggest a new therapeutic approach for patients with acute respiratory muscle dysfunction.

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: The authors thank Dr. M. Kivikko and Prof. P. Ryttila from Orion Pharma, Espoo, Finland, for providing levosimendan and placebo; N. Comtois from the Department of Medicine, Division of Critical Care Medicine, St. Michael’s Hospital, University of Toronto, Canada and Dr. H. van Dijk from the Department of Neurology, Radboud University Nijmegen Medical Centre, for technical assistance; J. van den Brule from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre, for performing the transthoracic echocardiography; and the research nurses from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre for assistance during the experiments.
References


